Leana  Wen net worth and biography

Leana Wen Biography and Net Worth

Director of Glaukos

Dr. Wen has served as a member of our Board of Directors since March 2021. Dr. Wen is an emergency physician and visiting professor of health policy and management at the George Washington University School of Public Health. She is also a contributing columnist for The Washington Post, writing on health policy and public health, and an on-air commentator for CNN as a medical analyst. From 2015 to 2018, she was the health commissioner for the city of Baltimore, where she led the nation’s oldest continuously operating health department to combat the opioid epidemic and improve maternal and child health. From 2013 to 2015, Dr. Wen served as director of patient-centered care research in the department of emergency medicine at George Washington University, and authored a critically-acclaimed book on patient advocacy. She has extensive experience on boards in nonprofit and governmental sectors and with venture-backed health innovation companies, and is currently on the board of the Bipartisan Policy Center and the Baltimore Community Foundation, and the advisory board of the Behavioral Health Group. She has also been a global health fellow at the World Health Organization, a consultant with the China Medical Board, the president of Planned Parenthood and a nonresident senior fellow at the Brookings Institution. Dr. Wen’s work has been recognized by numerous professional organizations, including as one of Modern Healthcare’s Top 50 Physician-Executives, and, in 2019, she was named one of TIME magazine’s 100 Most Influential People. Dr. Wen currently serves on the board of directors of UroGen Pharma Ltd. She holds a B.S. from California State University, Los Angeles, an M.D. from Washington University School of Medicine and two M.Sc.s from the University of Oxford, where she was a Rhodes Scholar. She completed her residency training at Brigham & Women’s Hospital and Massachusetts General Hospital, where she was a clinical fellow at Harvard Medical School.

What is Leana Wen's net worth?

The estimated net worth of Leana Wen is at least $2.63 million as of May 1st, 2026. Wen owns 19,739 shares of Glaukos stock worth more than $2,630,913 as of May 5th. This net worth estimate does not reflect any other investments that Wen may own. Learn More about Leana Wen's net worth.

How do I contact Leana Wen?

The corporate mailing address for Wen and other Glaukos executives is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. Glaukos can also be reached via phone at (949) 367-9600 and via email at [email protected]. Learn More on Leana Wen's contact information.

Has Leana Wen been buying or selling shares of Glaukos?

In the last ninety days, Leana Wen has sold $243,695.00 in Glaukos stock. Most recently, Leana Wen sold 1,700 shares of the business's stock in a transaction on Friday, May 1st. The shares were sold at an average price of $143.35, for a transaction totalling $243,695.00. Following the completion of the sale, the director now directly owns 19,739 shares of the company's stock, valued at $2,829,585.65. Learn More on Leana Wen's trading history.

Who are Glaukos' active insiders?

Glaukos' insider roster includes Thomas Burns (CEO), Mark Foley (Director), Joseph Gilliam (CFO), Gilbert Kliman (Director), Tomas Navratil (Chief Development Officer), Marc Stapley (Director), Alex Thurman (CFO), Aimee Weisner (Director), and Leana Wen (Director). Learn More on Glaukos' active insiders.

Are insiders buying or selling shares of Glaukos?

During the last year, insiders at the medical instruments supplier sold shares 15 times. They sold a total of 380,585 shares worth more than $44,455,497.21. The most recent insider tranaction occured on May, 1st when COO Joseph E Gilliam sold 19,573 shares worth more than $2,809,508.42. Insiders at Glaukos own 6.4% of the company. Learn More about insider trades at Glaukos.

Information on this page was last updated on 5/1/2026.

Leana Wen Insider Trading History at Glaukos

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/1/2026Sell1,700$143.35$243,695.0019,739View SEC Filing Icon  
See Full Table

Leana Wen Buying and Selling Activity at Glaukos

This chart shows Leana Wen's buying and selling at Glaukos by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Glaukos Company Overview

Glaukos logo
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
Read More

Today's Range

Now: $133.92
Low: $131.94
High: $137.87

50 Day Range

MA: $114.02
Low: $96.89
High: $142.95

2 Week Range

Now: $133.92
Low: $73.16
High: $146.75

Volume

436,782 shs

Average Volume

785,904 shs

Market Capitalization

$7.87 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.94